NCT07536048 2026-04-17
A Longitudinal Study of Epstein-Barr Virus (EBV) Reactivation in Adults Aged 18 to 29 Years
Sanofi
Not yet recruiting
Clinical Trials
10 trialsNCT07478952 2026-03-24
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age
ModernaTX, Inc.
Phase 1 Recruiting
NCT06256484 2026-03-11
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Atara Biotherapeutics
Phase 1 Terminated
NCT03394365 2026-02-20
ALLELE
Pierre Fabre Medicament
Phase 3 Recruiting
NCT04554914 2026-02-20
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
Pierre Fabre Medicament
Phase 2 Recruiting
NCT06761677 2026-02-05
A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma
SymBio Pharmaceuticals
Phase 1/2 Suspended
NCT05831111 2025-09-30
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants
ModernaTX, Inc.
Phase 1 Active not recruiting
NCT05011058 2025-07-28
NAVAL-1
Viracta Therapeutics, Inc.
Phase 2 Terminated
NCT05592626 2025-07-09
START-001
Marengo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05164094 2025-05-15
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults
ModernaTX, Inc.
Phase 1/2 Active not recruiting